Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder
NCT06672705Phase 1Recruiting
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epcoritamab in Post-Transplant Lymphoproliferative Disorder (PTLD). Primary endpoint: Incidence of adverse events. Started Jun 2025; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT06672705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672705.